In the present study, we have successfully developed and validated a radiomics nomogram for the pretreatment individualized prediction of anti-tumor efficacy in patients with advanced HCC and received PD-1 inhibitor therapy with three domestic drugs: Toripalimab, Camrelizumab, and Sintilimab. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.